Page 1 | Search Results | Blood | American Society of Hematology

1-7 of 7

Sort by

Sort Order Select

Journal Articles

Inpatient Versus Outpatient Hypomethylating Agent Induction for AML As a Predictor for Survival

Chetan Jeurkar, DO, Benjamin E Leiby, PhD, Joshua Banks, MS, Margaret Kasner, MDMSc, Gina Keiffer, MD, Lindsay Wilde, MD, Joanne Filicko-O'Hara, MD, Neil Palmisiano, MDMS

Blood (2020) 136 (Supplement 1): 27–28.

https://doi.org/10.1182/blood-2020-133837

Published: 2020

Journal Articles

Outcomes of Methotrexate-Associated T-Cell and NK/T-Cell Lymphoproliferative Disorders in Patients with a History of Rheumatological Disorders: A Retrospective Analysis of EBV-Association and Response to MTX Withdrawal

William T Johnson, DO, Danielle Garfunkel, B.S., Misung Yi, Benjamin E Leiby, PhD, Saritha Kartan, MD, Pierluigi Porcu, MD

Blood (2018) 132 (Supplement 1): 5347.

https://doi.org/10.1182/blood-2018-99-120070

Published: 2018

Journal Articles

Quantitative Sensory Testing in Children with Sickle Cell Disease

Robin E Miller, MD, Dawn S Brown, PCNS,FNP,CCRC, Sarah E Hegarty, MPhil, Scott W Keith, PhD, Benjamin E Leiby, PhD, Yamaja Setty, PhD, Suhita Gayen-Betal, PhD, Claudia M Campbell, PhD, Marie Stuart, MD

Blood (2017) 130 (Supplement 1): 3541.

https://doi.org/10.1182/blood.V130.Suppl_1.3541.3541

Published: 2017

Journal Articles

A Phase II Trial of Sirolimus with Standard Induction Chemotherapy in Patients with De Novo Acute Myeloid Leukemia

Neil Palmisiano, MD, Grace Jeschke, PhD, Benjamin E Leiby, PhD, Onder Alpdogan, MD, Matthew Carabasi, MD, Joanne Filicko-O'Hara, MD, Sameh Gaballa, MD, Dolores Grosso, DNP, CRNP, Thomas R. Klumpp, MD, Ubaldo Martinez Outschoorn, MD, John L Wagner, MD, Martin Carroll, MD, Pierluigi Porcu, MD, Neal Flomenberg, MD, Alexander E. Perl, MD, Margaret Kasner, MD

Blood (2017) 130 (Supplement 1): 3858.

https://doi.org/10.1182/blood.V130.Suppl_1.3858.3858

Published: 2017

Journal Articles

A Phase II Study of Azacitidine and Sirolimus for the Treatment of Acute Myeloid Leukemia (AML) Refractory to or Not Eligible for Intensive Chemotherapy or High Risk Myelodysplastic Syndrome (MDS)

Neil Palmisiano, MD, Grace Jeschke, PhD, Lindsay Wilde, MD, Benjamin E Leiby, PhD, Onder Alpdogan, MD, Matthew Carabasi, MD, Joanne Filicko-O'Hara, MD, Sameh Gaballa, MD, Dolores Grosso, DNP, CRNP, Thomas R. Klumpp, MD, Ubaldo Martinez Outschoorn, MD, John L Wagner, MD, Martin Carroll, MD, Pierluigi Porcu, MD, Neal Flomenberg, MD, Alexander E. Perl, MD, Margaret Kasner, MD

Blood (2017) 130 (Supplement 1): 4267.

https://doi.org/10.1182/blood.V130.Suppl_1.4267.4267

Published: 2017

Journal Articles

Metabolic Patterns in Cancer Cells and Tumor Microenvironment in Diffuse Large B-Cell Lymphoma: Tumor-Stromal Metabolic Coupling

Mahasweta Gooptu, MD, Alina E Dulau Florea, MD, Benjamin E Leiby, PhD, Barbara Pro, John David Sprandio, Jr., MD, Diana whittaker-Menezes, Paolo Cotzia, MD, Guldeep Uppal, MD, Jaime Caro, MD, Jerald Gong, MD, Ubaldo Martinez-Outschoorn, MD

Blood (2015) 126 (23): 3892.

https://doi.org/10.1182/blood.V126.23.3892.3892

Published: 2015

Journal Articles

Creatinine > 1.5 Mg/Dl and MDS Diagnosis Predicts Poor Outcome Following HSCT

Fern Martin, MD, Lekha Mikkilineni, MD, Kinjal Parikh, MD, Dolores Grosso, DNP, Benjamin E Leiby, PhD, Onder Alpdogan, MD, Matthew Carabasi, MD, Margaret Kasner, MD, Thomas R. Klumpp, MD, Ubaldo Martinez-Outschoorn, MD, Manish Sharma, MD, Mark Weiss, MD, John L. Wagner, MD, Neal Flomenberg, MD, Joanne Filicko-O'Hara, MD

Blood (2015) 126 (23): 3220.

https://doi.org/10.1182/blood.V126.23.3220.3220

Published: 2015

NARROW

Inpatient Versus Outpatient Hypomethylating Agent Induction for AML As a Predictor for Survival

Outcomes of Methotrexate-Associated T-Cell and NK/T-Cell Lymphoproliferative Disorders in Patients with a History of Rheumatological Disorders: A Retrospective Analysis of EBV-Association and Response to MTX Withdrawal

Quantitative Sensory Testing in Children with Sickle Cell Disease

A Phase II Trial of Sirolimus with Standard Induction Chemotherapy in Patients with De Novo Acute Myeloid Leukemia

A Phase II Study of Azacitidine and Sirolimus for the Treatment of Acute Myeloid Leukemia (AML) Refractory to or Not Eligible for Intensive Chemotherapy or High Risk Myelodysplastic Syndrome (MDS)

Metabolic Patterns in Cancer Cells and Tumor Microenvironment in Diffuse Large B-Cell Lymphoma: Tumor-Stromal Metabolic Coupling

Creatinine > 1.5 Mg/Dl and MDS Diagnosis Predicts Poor Outcome Following HSCT

Email alerts

ASH Publications

American Society of Hematology

Inpatient Versus Outpatient Hypomethylating Agent Induction for AML As a Predictor for Survival

Outcomes of Methotrexate-Associated T-Cell and NK/T-Cell Lymphoproliferative Disorders in Patients with a History of Rheumatological Disorders: A Retrospective Analysis of EBV-Association and Response to MTX Withdrawal

Quantitative Sensory Testing in Children with Sickle Cell Disease

A Phase II Trial of Sirolimus with Standard Induction Chemotherapy in Patients with De Novo Acute Myeloid Leukemia

A Phase II Study of Azacitidine and Sirolimus for the Treatment of Acute Myeloid Leukemia (AML) Refractory to or Not Eligible for Intensive Chemotherapy or High Risk Myelodysplastic Syndrome (MDS)

Metabolic Patterns in Cancer Cells and Tumor Microenvironment in Diffuse Large B-Cell Lymphoma: Tumor-Stromal Metabolic Coupling

Creatinine > 1.5 Mg/Dl and MDS Diagnosis Predicts Poor Outcome Following HSCT

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only